Bioptimus at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
- Kind of company
- Drug discovery and biologyAI that designs drugs, proteins and antibodies.
- Based in
- France
- Founded
- Not found in our sourcesBioptimus (company), Feb 20, 2024
- Last closed-round valuation
- No valuation reported
- What it has shipped
- Has a model or API
- Jean-Philippe Vert: co-founder and CEO; Chief R&D Officer of Owkin and former Research Lead at Google Brain (as of Feb 2024) (Bioptimus (company), Feb 20, 2024)
Released the Bioptimus SDK; earlier partnered with Cancer Research Horizons (Aug 2026). Oct 1, 2026
Shipped, or not yet.
“Has a model or API” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Feb 20, 2024 | Seed | $35 million | Not stated | Sofinnova Partners (lead), Bpifrance Large Venture, Frst, Cathay Innovation, Headline, Hummingbird, NJF Capital, Owkin, Top Harvest Capital, Xavier Niel | Bioptimus (company) |
| Jan 14, 2025 | Not named (extension; total $76 million) | $41 million | Not stated | Cathay Innovation (lead), Sofinnova Partners, Bpifrance Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Sunrise, Emmanuel Cassimatis, Thomas Wolf | Bioptimus (company) |
Worth knowing.
Our note: A pathology and multimodal biology model company rather than a drug developer, so no trial registry applies. Emerged from stealth 2024-02-20; founding year not stated. Company says H-Optimus-0 'consistently meets the performance or outperforms existing models' (company claim; no scores given). No 2025-2026 round beyond Jan 2025 found.
